UNSPSC 51434946: Hydrochlorothiazide/propranolol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434946 Hydrochlorothiazide/propranolol is a Commodity code reflecting state and local procurement of specific pharmaceutical formulations, though recent solicitations under this code span a broader range of emergency medications, generic pharmaceuticals, and over-the-counter products rather than the single-drug combination the code nominally describes. State and local governments purchase these medications through a mix of direct emergency-service procurement, cooperative purchasing agreements, and pharmacy benefit programs. Issuing bodies include municipal fire and rescue services (Tampa Fire Rescue), state health and human services agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). The medications are supplied through authorized wholesalers and direct manufacturer relationships, with strict requirements for expiration dating, quality assurance, cGMP certification, and DSCSA compliance. Vendors must maintain comprehensive product traceability by National Drug Code, manage chargeback systems with authorized distributors, and provide Safety Data Sheets compliant with OSHA standards.

Recent activity appears concentrated in the South and Upper Midwest. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, Diltiazem) due April 8, 2026, valued at $40,000, with a one-year term plus renewal options and a 5 percent bid discount for Small Local Business Enterprises. The Minnesota Department of Administration's Office of State Procurement issued an RFP through MMCAP in January 2026 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, with a two-year contract term effective July 1, 2026, distributed across authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson). The Texas Health and Human Services Commission issued an RFI in April 2026 to explore direct-to-manufacturer prescription contracting models outside traditional PBM and GPO channels, signaling potential future formalized procurement as the state develops detailed specifications and pricing frameworks.